Dynamo University 2025 Set to Spark Innovation and Connection With Keynote by Stefan Olander
Dynamo Software, a leader in alternative investments FinTech, is thrilled to announce key highlights of Dynamo University, an annual educational and networking event catering to the private investment industry. Taking place on May 15-16, 2025, in Boston at the Westin Copley Place, this year's agenda promises cutting-edge insights, dynamic discussions, and unparalleled opportunities for attendees to enhance their operations and forge new connections. The conference's agenda, which registrants can access via the mobile app, Dynamo EventsHub, is designed to facilitate full utilization of the FinTech capabilities integrated into Dynamo's end-to-end cloud platform.
Headlining Dynamo University 2025 is Stefan Olander, a globally recognized innovator in digital marketing and brand-building. Olander, known for his groundbreaking tenure at Nike, where he served as Vice President of Global Digital Innovation, has spearheaded projects like the revolutionary Nike+ FuelBand and the Apple Watch Nike+ experience. With a passion for blending consumer insight and digital transformation, Olander will deliver a keynote address that explores how innovation and creativity drive success in today's rapidly evolving landscape.
'We are honored to have Stefan Olander join us this year,' said Hank Boughner, CEO of Dynamo Software. 'His legacy of leveraging technology and storytelling to redefine consumer experiences resonates deeply with Dynamo's mission to empower private investment professionals through innovation and insights.'
Event Highlights:
NEW! The Dynamo Knowledge Pavilion | An immersive hub featuring product and support experts from Dynamo, the Pavilion is equipped to engage clients around end-to-end platform use cases, best practices, and roadmap reveals, Participants will learn how to optimize their use of Dynamo's end-to-end cloud platform to stay ahead in the competitive alternatives ecosystem.
Unveiling Dynamo 3.0 and Beyond | Get ready to explore the exciting new product enhancements, including Dynamo 3.0 and other innovative features designed to streamline workflows and elevate your organization's efficiency.
2 nd Annual DYNA-mite Awards | This awards program celebrates exceptional use of the Dynamo platform, honoring four distinctive client implementations.
Keynote by Stefan Olander | Attendees will hear firsthand insights from one of the marketing world's foremost innovators as he shares his expertise in creating revolutionary digital experiences.
Networking Event at Fenway Park | The timeless charm of America's oldest ballpark will be on display along with an exclusive evening of networking, refreshments, and camaraderie.
Attendees will have the opportunity to explore Dynamo's latest product advancements, including enhancements to UI/UX, Dynamo 3.0, AI capabilities, and updates to its fund accounting and analytics tools. Deep-dive breakout sessions will demonstrate the ins-and-outs of portfolio management, Dynamo Data Automation, investor relations, private market analytics, portfolio monitoring and valuation, and fundraising and marketing. Individual time with Dynamo configuration specialists will help users adapt solutions to meet their unique business needs.
Why Attend
Dynamo University 2025 is designed to provide clients with actionable insights and strategies to enhance their technology integration, boost efficiency, and unlock the full potential of their workflows. With dedicated General Partner (GP) and Limited Partner (LP) tracks, as well as sessions relevant to both groups, participants will leave empowered to tackle challenges and drive growth in the alternatives space.
'From the Knowledge Pavilion to Fenway Park, this year's conference delivers an unmatched blend of education and connection,' added Boughner. 'We're excited to create a meaningful experience for the Dynamo community to come together, learn from one another, and leave inspired.'
Passes for Dynamo University 2025 are available in limited quantities. Dynamo clients should plan to secure their seats no later than Friday, April 25 th, 2025.
About Dynamo Software, Inc.
Dynamo gives alternatives investors a Performance Edge, empowering them to efficiently scale their firm to capitalize on the growing wave of private market opportunities. With the Dynamo Alternative Investment Platform, Limited and General Partners can now run a tightly integrated firm, putting all their data to work to accelerate operations across front, middle, and back office, unleashing teams to work smarter, and allowing leaders to make better investment decisions and scale their firm. Dynamo has a global footprint with operations across North America, EMEA, APAC, and UAE. For more information, please visit DynamoSoftware.com.
Nicole Selinger
314-805-2165
SOURCE: Dynamo Software, Inc.
Copyright Business Wire 2025.
PUB: 04/10/2025 07:03 AM/DISC: 04/10/2025 07:03 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hypebeast
2 hours ago
- Hypebeast
Better Gift Shop's Nike Collaboration Is Destiny Fulfilled
Brands have become increasingly connected with the world, establishing their presence via flagship storefronts, exclusive launches, pop-up activations, wide-reaching social media pages, and more. However, the true cornerstones of communities are locally owned spaces. For Toronto,Better Gift Shopis just that. Since 2017, theAvi Gold-led imprint has operated as a platform for key creative and cultural moments, leveraging collaboration to contextualize global works locally. Designed as the gift shop to a fictional museum, the label has assembled its most significant initiative to date, teaming up withNiketo put its spin on theAir Max Dn8. Inspired by the concept of revenge, the sneaker dons an aggressive appearance that enhances the streamlined silhouette with strong linework. In the brand's words, the shoe's glacial composition of gray and blue reflects how 'revenge is a dish best served cold.' To explore the campaign, we connected with Gold himself, who not only breaks down the shoe's various points of inspiration but also addresses his longstanding history with the Swoosh and how he manifested this powerful moment. Better Gift Shop has an extensive history of collaboration; however, this is its first collaboration with Nike. Was teaming up with the Swoosh a goal of yours at any point? It has always been our goal to work with Nike, something we have manifested for years. The brand was generous enough to give us 'Crystal Blue' Air Max 95s to gift our friends, and eventually, a few years later, they approached us to open an account. Ever since then, we have been able to collaborate on activations with Nike as well. 'We're all driven by nostalgia but ultimately want to focus on pushing forward.' The Nike Air Max Dn8 is the focal point of this project. What about the model speaks to you, and what makes it the right fit for Better Gift Shop? When Nike releases new silhouettes, everyone is quick to offer strong opinions. When I first saw the shoe, I knew I would be interested in it because I could see where the design references came from: the Air Max 2001, Air Max 96, etc. We're all driven by nostalgia but ultimately want to focus on pushing forward, so its acknowledgment of the past while delivering a futuristic look made it a great fit. When putting the collaboration together, what was your starting point? It all began with a conversation I had at Nike's World Headquarters in Beaverton, discussing all of the doubts I've experienced in all my years in the industry and the moments of disappointment. The following day, while in the Department of Nike Archives, myself and Teddy [Better Gift Shop's lead designer on the project] gravitated towards footwear moments that left lasting impressions on us — Spiridons from 1997, Vince Carter's Shox, and then seeing one of the original colorways of the Air Max 2001, which seems like a significant driving force in the inspiration for the Air Max Dn8. We paid homage to these key moments with details like the reflective, Spiridon-inspired lace loops and other 'effects' that speak to the aesthetics I enjoy as a fan of Nike. 'I stayed in touch with people from [Nike], but never imagined things landing where they have.' This iteration of the shoe draws inspiration from your journey with Nike. Could you elaborate more on this connection? Back in the day, I worked retail at the Nike Store on Bloor Street in Toronto. Knowing my love for the Air Max 95, Nike contacted me to host an activation based on the Air Max 95 after the ball got rolling on Better Gift Shop. I stayed in touch with people from the brand, but never imagined things landing where they have. It's still wild to consider that they trusted us to create an incredible product. Above all else, I am a fan of the brand. In the early nineties, my late uncle worked for Nike as an international sales rep, and he gifted me my first pair ever, so the brand holds a very special place in my heart. The shoe features a lenticular tongue design inspired by a friend of the brand who lives in Japan. What's the story behind that detail? I must credit my friend in Tokyo, Esqwe, for his idea. He makes lenticular pins and stickers, including designs for incredible people and brands. We were contemplating how to capture both logos simultaneously in a cool, unconventional way when it finally struck: make it lenticular! [laughs] I bought aBeavis and Butt-Headtee as a kid in Buffalo, New York. It had a lenticular patch sewn on it and always stuck with me as something nostalgic and cool. For this project, you created Revengie, your very own character who arrives in the form of a plushie and vinyl collectible statue, both of which appear in the campaign. Where did the inspiration for this come from? This concept was the idea of my friend Zirchi Gray, an incredible artist in Tokyo who is originally from Virginia. He moved to Tokyo years ago and adopted incredible illustration techniques, capturing moments in ways that are uncanny. We were going for the aesthetic of retro Japanese animated characters and looked to encapsulate it in a timeless, fun way. Zirchi pushed us to do the statue, plushie, and vinyl toys. We were obsessing over how to make things even more interesting and exciting for the consumer, and this landed exactly where we wanted to go with it. Earl Sweatshirt also appears in the campaign. What was it like working with him, and how did he get involved? Earl is a friend and is one of the most interesting and talented people I've ever met. Casting him for the project felt natural, as I've always appreciated his perspective, no matter the context, so it was a simple no-brainer. I'm incredibly grateful that he was willing to do this with us. He is very intentional, so having him involved is an honor. The campaign also includes apparel and accessory components. Can you walk me through the range? We were lucky that Nike let us flip some iconic staples with Better graphics, but there are also mythical items for promotional use only. We made the custom plushie, lapel pins, stickers, and, fingers crossed, a vinyl toy made in Japan that will launch at a Tokyo activation we're preparing. We also tied on items that are true to us: a special edition hat, a bandana with Geek Out Store, and custom basketball shorts. What sort of feeling do you hope people get when wearing the shoe? I hope this moment, story, and project all feel exciting, and that the sneakers feel special when you put them on. We needed to bring excitement to the people. Nike is tapping into 'the feeling' again. We saw it with the big bubble Air Max 95s and many others. My hope is for these Air Max Dn8s to be a point of recognition and distinction, like, 'Oh sh*t, you got the Better Dn8s!' The Better Gift Shop x Nike Air Max Dn8 launches exclusively viaBetter Gift Shopon June 13 alongside its accompanying apparel collection. From there, Nike SNKRS will host a drop on June 20.
TechCrunch
2 hours ago
- TechCrunch
Europe, we're not leaving. Period.
There are some headlines making the rounds claiming that TechCrunch is 'pulling out of Europe' and shuttering its coverage of European startups. This is flat-out wrong. It misrepresents who we are, what we do, and — most of all — what we believe. The recent changes at TechCrunch are not about retreat. They are about realignment and reinforcement. This new chapter is fueled by our partnership with our sister company, Foundry, which was brought under the same ownership to create a tech media entity with unparalleled global scope. To be clear, Foundry is a powerhouse of international technology journalism. Its portfolio includes established and respected brands like PCWorld, Macworld, CIO, and TechAdvisor, with a vast network of journalists and deep-rooted expertise in local and regional tech ecosystems across Europe and the world. The suggestion that our new ownership believes international coverage is unessential is patently false. The entire purpose of bringing TechCrunch and Foundry together is to create a stronger, more globally focused media platform. Why we fight for this beat Europe is where fintech regulation is rewritten, where quantum startups spin out of Max Planck labs, where climate-tech pilots become the standard for the rest of the planet. In 2024 alone, European founders raised over €40 billion; many of the unicorns we covered last year were born on this continent. If you care about the future of technology, you have to be here. And we are. As we integrate the strengths of both TechCrunch and Foundry, here is our promise to the founders, investors, and readers in Europe and beyond: Radical presence. We will be on the ground — from demo days in Tallinn to hydrogen-hub unveilings in the Basque Country — because stories look different up close. We will be on the ground — from demo days in Tallinn to hydrogen-hub unveilings in the Basque Country — because stories look different up close. Relentless scrutiny. Hype dies in daylight. We'll keep asking the annoying questions and digging for the real story so you don't have to. Hype dies in daylight. We'll keep asking the annoying questions and digging for the real story so you don't have to. A true global megaphone. A breakthrough in Zagreb deserves the same volume as one in Silicon Valley. By merging the TechCrunch and Foundry networks, we will amplify European innovation to millions more readers in 190+ countries, providing deeper insights and a truly unified global vision. To the startup community: Keep your tips, term sheets, and tantrums coming. Send them to tips@ or ping our encrypted channels. We'll be listening — louder and more broadly than ever. Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW TechCrunch isn't retreating from Europe. We're doubling down. — Michael Reinstein, Chairman and Publisher
Yahoo
3 hours ago
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@
